Home › BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
 

Keywords :   


BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

2014-09-07 03:43:00| Biotech - Topix.net

BioCryst Pharmaceuticals, Inc. today announced trial results related to RAPIVAB , a neuraminidase inhibitor for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014. "Based on clinical trial data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said presenting author Richard Whitley, M.D , University of Alabama at Birmingham.

Tags: the results meeting treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Tropical Storm Joyce Graphics
29.09Tropical Storm Joyce Forecast Advisory Number 9
29.09Summary for Tropical Storm Joyce (AT1/AL112024)
29.09Hurricane Isaac Graphics
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Oasis ticket seller and promoter bosses get 14.8m
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
More »